Search company, investor...

Predict your next investment

Corporation
fresenius-kabi.com

Partners & Customers

10

About Fresenius Kabi

Fresenius Kabi is focused on the therapy and care of critically and chronically ill patients inside and outside the hospital. Its portfolio comprises a wide range of IV drugs, infusion therapies, clinical nutrition products as well as the related medical devices. For transfusion technology, Fresenius Kabi offers a range of products used by blood banks and blood donation units to produce blood products.

Headquarters Location

Else-Krener-Strasse 1

Bad Homburg, 61352,

Germany

+49 6172 686 0

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Expert Collections containing Fresenius Kabi

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Fresenius Kabi in 1 Expert Collection, including Conference Exhibitors.

C

Conference Exhibitors

5,302 items

Latest Fresenius Kabi News

Psoriatic Arthritis Pipeline Insights Report 2024 | Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics,Amgen, Zydus cedilla, Sandoz, Shanghai Henlius Biotech and others

Feb 19, 2024

DelveInsight’s, “Psoriatic Arthritis Pipeline Insight 2024” report provides comprehensive insights about 50+ Psoriatic Arthritis companies and 50+ pipeline drugs in the Psoriatic Arthritis pipeline landscape. It covers the Psoriatic Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriatic Arthritis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Psoriatic Arthritis Pipeline Report DelveInsight’s Psoriatic Arthritis pipeline report depicts a robust space with 50+ Psoriatic Arthritis companies working to develop 50+ pipeline therapies for Psoriatic Arthritis treatment. The leading companies working in the Psoriatic Arthritis Market include Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics, Amgen, Zydus cedilla, Sandoz, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Fresenius Kabi, Torrent Pharmaceuticals, Cipla, Biogen, AbbVie, Biocad, Boehringer Ingelheim, Sun Pharma Global, Gilead Sciences, UCB Biopharma, Formycon, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, Synact Pharma, NeuClone, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Akeso Biopharma, Polpharma Biologics, Avotres, Bio-Thera Solutions, Xbrane Biopharma, XBiotech, Innovimmune Biotherapeutics, Aclaris Therapeutics, Luye Pharma Group, Evelo, Levolta Pharmaceuticals, DNX Biopharmaceuticals, Mycenax Biotech, and others. Promising Psoriatic Arthritis Pipeline Therapies in the various stages of development include NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, Methotrexate (MTX), and others. September 2023: ACELYRIN Inc. announced a study of phase 2 & 3 clinical trials for Izokibep. Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA). This study will evaluate the efficacy of izokibep in subjects with PsA. September 2023: Novartis Pharmaceuticals announced a study of phase 3 clinical trials for Secukinumab and Ustekinumab. The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment. Request a sample and discover the recent advances in Psoriatic Arthritis Treatment Drugs @  Psoriatic Arthritis Pipeline Report In the Psoriatic Arthritis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriatic Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Psoriatic Arthritis Overview Psoriatic Arthritis is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops gradually and cause more nuisance than disabling. Psoriatic arthritis is considered as seronegative spondyloarthropathies. ABT-494: AbbVie Psoriatic ArthritisTherapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Psoriatic Arthritis Companies- Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics, Amgen, Zydus cedilla, Sandoz, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Fresenius Kabi, Torrent Pharmaceuticals, Cipla, Biogen, AbbVie, Biocad, Boehringer Ingelheim, Sun Pharma Global, Gilead Sciences, UCB Biopharma, Formycon, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, Synact Pharma, NeuClone, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Akeso Biopharma, Polpharma Biologics, Avotres, Bio-Thera Solutions, Xbrane Biopharma, XBiotech, Innovimmune Biotherapeutics, Aclaris Therapeutics, Luye Pharma Group, Evelo, Levolta Pharmaceuticals, DNX Biopharmaceuticals, Mycenax Biotech, and others. Psoriatic Arthritis Pipeline Therapies- NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, Methotrexate (MTX), and others.

Fresenius Kabi Acquisitions

5 Acquisitions

Fresenius Kabi acquired 5 companies. Their latest acquisition was Ivenix on March 31, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/31/2022

Series E+

$99M

$96.44M

Acquired

6

3/31/2022

Subscribe to see more

$99M

Subscribe to see more

10

1/8/2016

Subscribe to see more

$99M

Subscribe to see more

10

5/13/2014

Subscribe to see more

$99M

Subscribe to see more

10

7/23/2012

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/31/2022

3/31/2022

1/8/2016

5/13/2014

7/23/2012

Investment Stage

Series E+

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$96.44M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

10

10

10

10

Fresenius Kabi Partners & Customers

10 Partners and customers

Fresenius Kabi has 10 strategic partners and customers. Fresenius Kabi recently partnered with Mayo Clinic on December 12, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

12/14/2023

Client

United States

Fresenius Kabi, Mayo Clinic Strike Deal for Ivenix Infusion Pumps

Fresenius Kabi said this is the biggest contract for Ivenix pumps the company has signed to date .

2

9/14/2023

Client

United States

Fresenius : Kabi signed an agreement with Virginia Oncology Associates to deliver Ivenix Infusion System

Fresenius Kabi : Kabi signed an agreement with Virginia Oncology Associates to deliver Ivenix Infusion System

2

8/24/2023

Client

United States

Fresenius Kabi and Lupagen enter into strategic development and supply agreement to bring cell and gene therapies to the bedside - Fresenius Kabi Global

Fresenius Kabi and Lupagen Inc. announced today that the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside .

1

8/7/2023

Licensor

Germany

Subscribe to see more

Subscribe to see more

10

5/1/2023

Client

United States

Subscribe to see more

Subscribe to see more

10

Date

12/14/2023

9/14/2023

8/24/2023

8/7/2023

5/1/2023

Type

Client

Client

Client

Licensor

Client

Business Partner

Country

United States

United States

United States

Germany

United States

News Snippet

Fresenius Kabi, Mayo Clinic Strike Deal for Ivenix Infusion Pumps

Fresenius Kabi said this is the biggest contract for Ivenix pumps the company has signed to date .

Fresenius : Kabi signed an agreement with Virginia Oncology Associates to deliver Ivenix Infusion System

Fresenius Kabi : Kabi signed an agreement with Virginia Oncology Associates to deliver Ivenix Infusion System

Fresenius Kabi and Lupagen enter into strategic development and supply agreement to bring cell and gene therapies to the bedside - Fresenius Kabi Global

Fresenius Kabi and Lupagen Inc. announced today that the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

2

1

10

10

Fresenius Kabi Team

25 Team Members

Fresenius Kabi has 25 team members, including current Chief Executive Officer, Muhammad Asif.

Name

Work History

Title

Status

Muhammad Asif

Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Muhammad Asif

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Chief Executive Officer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.